Artiva Biotherapeutics closed at $4.22 on Nov 4, up 0.48%, 68.5% below its 52-week closing high. Volume of 754.3K shares was 0.66× its 20-day average (below normal).
Split-adjusted performance: -42.0% over one month, -65.9% over six months, +11.9% over one year.
Short interest was 2.7M shares at the Oct 15 settlement, up 19.2% from the prior report (20.1% of float, 6.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ARTVArtiva Biotherapeutics | $4.22 | +0.48% | −65.9% | — | — | — | $206.3M | |
| PLXProtalix BioTherapeutics | $2.69 | +3.07% | +33.2% | +27.1% | 19.0% | 11.4 | $216.7M | Compare |
| PALIPalisade Bio | $1.25 | +1.63% | −37.5% | — | −2114.8% | — | $217.8M | Compare |
| IKTInhibikase Therapeutics | $1.57 | +5.74% | −22.1% | — | — | — | $218.4M | Compare |
| DTILPrecision BioSciences | $8.12 | +16.50% | +8.0% | −100.0% | — | — | $224.1M | Compare |
| IVVDInvivyd | $0.6336 | +8.96% | −56.6% | +21.2% | −310.8% | — | $186.8M | Compare |
| ACOGAlpha Cognition | $8.53 | +4.02% | +33.7% | +267.6% | −144.3% | — | $185.8M | Compare |
| PROKProKidney | $1.12 | +4.67% | −42.9% | −32.1% | −18948.0% | — | $234.1M | Compare |
| CABACabaletta Bio | $1.42 | 0.00% | −61.9% | — | — | — | $240.8M | Compare |
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
